Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73% Market Closed
Market Cap: 457.1m GBX

Net Margin
Amryt Pharma Holdings Ltd

-41.6%
Current
-88.9%
Average
5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-41.6%
=
Net Income
-87.5m
/
Revenue
210.2m

Net Margin Across Competitors

Amryt Pharma Holdings Ltd
Glance View

Market Cap
453.2m GBX
Industry
Pharmaceuticals

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.

AMYT Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-41.6%
=
Net Income
-87.5m
/
Revenue
210.2m
What is the Net Margin of Amryt Pharma Holdings Ltd?

Based on Amryt Pharma Holdings Ltd's most recent financial statements, the company has Net Margin of -41.6%.

Back to Top